Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 1:39 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 126 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Cerebellar Degeneration Clear all

Conditions: Friedreich's Ataxia
Interventions: Placebo, EPI-743 400 mg, EPI-743 200 mg; Drug
Lead sponsor: PTC Therapeutics; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 3
States / cities: Los Angeles, California • Tampa, Florida • Philadelphia, Pennsylvania

Conditions: Friedreich Ataxia
Interventions: Methylprednisolone; Drug
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: 5 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Friedreich's Ataxia
Interventions: Cardiac magnetic resonance imaging (CMR), Exercise-stress test, Echocardiogram (ECHO), Cardiac-related blood studies; Procedure
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 12 Years to 50 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: Spinocerebellar Ataxia - All Sub-types, Friedreich's Ataxia
Interventions: Ataxia rating scale; Other
Lead sponsor: University of South Florida; Other
Eligibility: 18 Years to 80 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Trigeminal Nerve Injuries, Post-herpetic Neuralgia, Facial Pain, Nervus Intermedius Neuralgia
Interventions: transcranial magnetic stimulation; Device
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years to 110 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Friedreich Ataxia, Cardiomyopathies, Central Nervous System Diseases, Neuromuscular Diseases, Mitochondrial Diseases, Mitochondrial Dysfunction, Genetic Disease
Interventions: ATI-105, Placebo; Drug
Lead sponsor: Adjuvia Therapeutics, Inc.; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Spinocerebellar Ataxia Type 6
Interventions: Not listed
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Friedreich's Ataxia
Interventions: RT001, Placebo; Drug
Lead sponsor: Biojiva LLC; Industry
Eligibility: 12 Years to 50 Years
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 6
States / cities: Long Beach, California • Los Angeles, California • Gainesville, Florida + 3 more

Conditions: Friedreich Ataxia
Interventions: Rosuvastatin; Drug
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: 18 Years to 65 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Friedreich Ataxia
Interventions: Omaveloxolone, Placebo; Drug
Lead sponsor: Biogen; Industry
Eligibility: 2 Years to 15 Years
Enrollment: 255 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 7
States / cities: Los Angeles, California • Gainesville, Florida • Tampa, Florida + 4 more

Conditions: Spinocerebellar Ataxia (SCA)
Interventions: Not listed
Lead sponsor: BioSensics; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 2
States / cities: Lutherville, Maryland • New York, New York

Conditions: Spinocerebellar Ataxia Type 1, Spinocerebellar Ataxia Type 2, Spinocerebellar Ataxia Type 3, Spinocerebellar Ataxia Type 6, Friedreich Ataxia
Interventions: Not listed
Lead sponsor: University of Chicago; Other
Eligibility: 12 Years to 75 Years
Enrollment: 128 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2024
U.S. locations: 5
States / cities: Los Angeles, California • Chicago, Illinois • Baltimore, Maryland + 2 more

Conditions: Spinocerebellar Ataxia
Interventions: Transcranial Magnetic Stimulation; Device
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 18 Years to 70 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Cerebellar Ataxia
Interventions: Aerobic Training, Balance Training; Behavioral
Lead sponsor: Columbia University; Other
Eligibility: 18 Years and older
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: New York, New York

Conditions: Spinocerebellar Ataxias
Interventions: BHV-4157; Drug
Lead sponsor: Biohaven Therapeutics Ltd.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 909 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Friedreich Ataxia
Interventions: Not listed
Lead sponsor: Friedreich's Ataxia Research Alliance; Other
Eligibility: Not listed
Enrollment: 3,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2048
U.S. locations: 9
States / cities: Los Angeles, California • Denver, Colorado • Gainesville, Florida + 6 more

Conditions: Friedreich Ataxia
Interventions: CTI-1601, Placebo; Biological · Other
Lead sponsor: Larimar Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Eatontown, New Jersey

Conditions: CACNA1A, Spinocerebellar Ataxia Type 6, Episodic Ataxia Type 2, Familial Hemiplegic Migraine-1
Interventions: N-Acetyl-L-Leucine, Placebo; Drug · Other
Lead sponsor: IntraBio Inc; Industry
Eligibility: 4 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 3
States / cities: Baltimore, Maryland • Boston, Massachusetts • Houston, Texas

Conditions: Friedreich Ataxia
Interventions: Idebenone; Drug
Lead sponsor: National Institute of Neurological Disorders and Stroke (NINDS); NIH
Eligibility: 9 Years to 17 Years
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Cerebellar Disorders, Cerebellar Degeneration, Cerebellar Atrophy, Cerebellar Lesions
Interventions: High-intensity training in variable contexts, Conventional balance training; Other
Lead sponsor: Indiana University; Other
Eligibility: 18 Years to 85 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Friedreich Ataxia
Interventions: Idebenone; Drug
Lead sponsor: National Institute of Neurological Disorders and Stroke (NINDS); NIH
Eligibility: Not listed
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2006
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Friedreich Ataxia
Interventions: Omaveloxolone; Drug
Lead sponsor: Biogen; Industry
Eligibility: 16 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 4
States / cities: Los Angeles, California • Aurora, Colorado • Gainesville, Florida + 1 more

Conditions: Unresectable or Metastatic Microsatellite Stable (MSS) Solid Tumor, Microsatellite Stable (MSS) Colon Cancer
Interventions: Copanlisib, Nivolumab; Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Spinocerebellar Ataxia Type 1, Spinocerebellar Ataxia Type 2, Spinocerebellar Ataxia Type 3, Spinocerebellar Ataxia Type 6, Spinocerebellar Ataxia Type 7
Interventions: High-Intensity Aerobic Exercise Prior to Balance Training, Low-Intensity Exercise Prior to Balance Training; Behavioral
Lead sponsor: Teachers College, Columbia University; Other
Eligibility: 18 Years to 85 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: New York, New York

Search by objective public record fields.

Safety and Efficacy of EPI-743 in Patients With Friedreich's Ataxia

Methylprednisolone Treatment of Friedreich Ataxia

Characterization of the Cardiac Phenotype of Friedreich's Ataxia (FRDA)

Preliminary Study of the Scale To Assess Ataxia and Neurologic Dysfunction (STAND)

Transcranial Magnetic Stimulation for Facial Pain

A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of ATI-105 in Healthy Adults

Parkinsonism in Spinocerebellar Ataxia Type 6

A Study to Assess Efficacy, Long Term Safety and Tolerability of RT001 in Subjects With Friedreich's Ataxia

Rosuvastatin (Crestor) in Friedreich Ataxia

A Study to Learn More About the Effects and Long-Term Safety of Omaveloxolone (BIIB141) in Children and Teens With Friedreich's Ataxia

Multi-Modal Digital Monitoring of Disease Symptoms in Spinocerebellar Ataxia

Instrumented Data Exchange for Ataxia Study

Transcranial Magnetic Stimulation in Spino-Cerebellar Ataxia

Training in Ataxia - Individuals With Degenerative Cerebellar Diseases

Real-World Data Study of Troriluzole-Treated Patients With Spinocerebellar Ataxia (SCA) Compared to a Matched Natural History Control

Friedreich Ataxia Global Clinical Consortium UNIFIED Natural History Study

A Double-Blind, Placebo-Controlled, Dose Exploration Study of CTI-1601 in Adult Subjects With Friedreich's Ataxia

Pivotal Study of N-acetyl-L-leucine for CACNA1A

Idebenone to Treat Friedreich's Ataxia

Variable Intense Training for Ataxia and Locomotion

Safety Study of Idebenone to Treat Friedreich's Ataxia

A Study to Learn More About the Long-Term Safety of BIIB141 (Omaveloxolone) in Participants With Friedreich's Ataxia Who Are Prescribed it by Their Own Doctors

Study of PI3Kinase Inhibition (Copanlisib) and Anti-PD-1 Antibody Nivolumab in Relapsed/Refractory Solid Tumors With Expansions in Mismatch-repair Proficient (MSS) Colorectal Cancer

Priming Motor Learning Through Exercise in People With Spinocerebellar Ataxia